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Abstract 
 
Purpose: To compare the outcomes of pediatric and adolescent extracranial malignant 
germ cell tumor (GCT) patients treated with either carboplatin and cisplatin on clinical 
trials conducted by Children’s Oncology Group (COG) and the Children’s Cancer and 
Leukemia Group (CCLG). 
 
Methods: The Malignant Germ Cell International Consortium (MaGIC) has created a 
database of the GCT clinical trials conducted since 1983 by COG (United States, Canada, 
Australia), which has used cisplatin-based regimens, and by CCLG (United Kingdom), 
which has used carboplatin-based regimens. Using the parametric cure model, this study 
compared the overall 4-year event-free survival (EFS), stratified by age, stage, site, and 
the a-priori defined MaGIC ‘risk’ groups: standard risk ((SR) 1 (EFS >80%; age < 
11years) , SR2 (EFS >80%, age >11y), and poor risk (EFS <70%, age >11y).  
 
Results:  Cisplatin-based therapy was used in 620 patients; carboplatin was used in 163 
patients. In the overall multivariate cure model, the two regimens did not differ 
significantly (cisplatin: 4y-EFS 86%; 95% confidence interval (CI) 83-89% vs. 
carboplatin 4y-EFS 86%; 95% CI 79-90%; p=0.87). No significant differences were 
noted in stratified analyses by site, stage, age and MaGIC risk group: SR1 (p=0.20), SR2 
(p=0.55) or PR (p=0.72) patients. 
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Conclusions: In these trials conducted contemporaneously, there is no significant 
difference in outcome observed overall, or any subset of patients who were treated with 
regimens containing cisplatin  vs. carboplatin. A randomized trial to evaluate the 
effectiveness of carboplatin vs. cisplatin in the treatment of children, adolescents and 
young adults with standard risk GCT is underway. 
 
Word count: 250  
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Introduction 
After the landmark study by Einhorn et al. 1  in 1977, cisplatin-based therapy was rapidly 
accepted as the standard of care for testicular cancer, and testicular cancer became “the 
model of a curable neoplasm” 2.  However, cure comes with the price of significant 
immediate and often permanent toxicities, including hearing loss, tinnitus, peripheral 
neuropathy, and nephrotoxicity.3 With longer follow-up, cisplatin has been associated 
with reduced fertility, at least in males, 4 and testicular cancer survivors have a two-fold 
increase in risk of second malignant solid neoplasms (in addition to the established risk of 
etoposide-induced leukemias) and early onset of cardiovascular disease.5,6  
 
Other platinum-based compounds were developed, with the hope that a less toxic 
alternative to cisplatin could be found. Carboplatin appeared to be a promising 
alternative, causing less oto- and nephrotoxicity.  Four randomized clinical trials (RCTs) 
of carboplatin vs. cisplatin were conducted in the late 1980s in adult men with good-risk 
non-seminomatous testicular germ cell tumors.7-10 Unfortunately, carboplatin was inferior 
to cisplatin in every trial. However, at the same time that carboplatin was being 
investigated in adult men with testicular cancer, carboplatin was also adopted for the 
treatment of germ cell tumors (GCTs) in children and adolescents by several pediatric 
clinical trial groups. As summarized by Shaikh et al,11 in the three pediatric studies that 
used carboplatin at a higher dose and frequency than used in the adult trials of carboplatin 
in men with testicular cancer, 158/179 (88%) of children remained event-free. However, 
because none of the pediatric trials that have used carboplatin were randomized, the 
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relative effectiveness of carboplatin vs. cisplatin for children and adolescents with GCT 
remains unclear. 
 
In 2010, investigators from the Children’s Oncology Group (COG) (United States, 
Canada and Australia) and the Children’s Cancer and Leukemia Group (CCLG) (United 
Kingdom) created the Malignant Germ Cell International Consortium and agreed to pool 
25 years of clinical trial data on pediatric and adolescent GCTs. Analysis of the MaGIC 
data identified three factors that predicted worse outcome: age 11 years or more, 
advanced stage of disease and either an ovarian or an extragonadal primary.12 MaGIC 
proposed a new risk stratification that re-classified pediatric and adolescent GCT into 
standard (EFS >80%) and poor (EFS <70%) risk groups based on these clinical 
features.12 In this study, we compare the outcomes of treatment with carboplatin vs. 
cisplatin, overall and by site, stage, age as well as in the previously defined by MaGIC 
risk groups.  
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Methods 
Patients 
Details of MaGIC have been reported elsewhere.12 Briefly, patients with extracranial 
malignant GCTs treated on clinical trials conducted by either the CCLG or COG between 
1983 and 2008 were included in the MaGIC dataset, including CCLG GC1 and GC8901 
(GC2) from the UK and INT0097, INT0106, P9747, AGCT01P1, and AGCT0132 from 
the COG (Supplemental Table 1).  
 
In the CCLG clinical trials, the regimen ‘JEB’ consisted of carboplatin 600 mg/m2 (AUC 
7.9), etoposide 360 mg/m2 and bleomycin 15 mg/m2 given every 21 days for n+2 cycles 
(where n is the number of cycles needed to achieve marker normalization; median =5). In 
the COG, the regimen ‘PEb (or pediatric-BEP) consisted of cisplatin 100 mg/m2, 
etoposide 500 mg/m2 and bleomycin 15mg/m2 every 21 days. The number of days over 
which the total dose of PEb was delivered and the number of cycles (3-6) varied between 
protocols. One COG trial added another agent (cyclophosphamide - AGCT01P1); another 
COG trial tested high-dose cisplatin (200 mg/m2 per cycle - INT0097). Further details of 
the therapies delivered on each trial are summarized in Supplemental Table 1.   
 
Inclusion in this analysis required that a patient had been treated with a platin-based 
regimen, and that the primary tumor contained malignant non-germinomatous GCT 
histology (i.e. yolk sac tumor, choriocarcinoma, or embryonal carcinoma). There were a 
total of 1300 patients in the seven studies. The upper age limit varied from age 15y on 
CCLG trials to 21y on most trials in COG (see Supplemental Table 1). Stage I patients 
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who were initially treated with surgery and active surveillance, but who were 
subsequently treated with chemotherapy because of recurrent disease, were excluded 
from this analysis (n=69), because of the very high rate of salvage in this group, on both 
regimens.13,14,15 Stage I patients who received chemotherapy immediately following 
surgery however, as was standard practice for certain sites (extragonadal and ovarian), 
were included. Patients treated with surgery only (n=363) or non-platin-based 
chemotherapy (n=4), those with either pure immature teratoma (n=11) or pure 
seminoma/dysgerminoma (n=68), and those with missing data on stage (n=2) were 
excluded from the analysis. After exclusions, the dataset included 783 patients. 
 
Statistical analysis 
Outcome Measure: Event-free survival (EFS): Patient outcome was calculated as time 
from the start of chemotherapy until disease progression, diagnosis of a second malignant 
neoplasm (SMN) death, or date of last follow-up, whichever came first. A patient who 
experienced disease progression, SMN or death was an event for the analysis; otherwise, 
the patient was censored at last contact. 
 
Statistical Model: A non-mixture cure model was used to model the relationship between 
treatment and EFS. 13 This model has been shown to provide excellent fit to childhood 
cancer outcome data. The model provides a coherent methodology to investigate the 
effects of treatment on rate of failure separately from their effect on ultimate cure. A 
model with a Weibull kernel with no covariates and cured fraction modeled as a logistic 
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function of the patient characteristics was used.  This was the same model used in 
previous MaGIC analyses18. 
 
The Kaplan-Meier estimate of proportion event-free as a function of time since the start 
of follow-up was calculated for selected groups of patients. The log rank test was used to 
compare equality of risk across selected patient groups.16 The parametric and non-
parametric estimators of EFS as a function of time were compared as suggested by 
Sposto et al.17 The hazard ratio (HR) of patients treated with JEB relative to PEb was 
estimated by Cox regression. For comparisons where the maximum likelihood estimate of 
the HR did not converge, the method of Firth18 was applied to obtain a finite estimate of 
HR and its 95% confidence interval.  A two-sided p-value of 0.05 or less s identified as 
significant. 
 
Covariates:  
 
MaGIC-defined risk groups: The significant prognostic factors (age ≥11y, advanced stage 
and either ovarian or extragonadal site) identified in the previous MaGIC risk 
stratification were used to construct two risk groups: standard risk (SR) (EFS> 80%) and 
poor risk (PR) (EFS <70%).12 The standard risk group is divided by age into two further 
categories. Patients age 10y or less are in the SR1 group, which includes COG stage II-IV 
and all sites (ovarian, extragonadal, and testicular). Patients age 11y and older with COG 
stage II-III ovarian, stage II extragonadal and IGCCC good risk testicular are in the SR2 
group. The poor risk group is comprised of patients age 11y and older with COG stage IV 
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ovarian, COG stage III-IV extragonadal, and IGCCC intermediate and poor risk 
testicular. The outcomes of patients treated on JEB vs. PEb were compared in these three 
summary MaGIC risk groups. 
 
Other covariates: Age was dichotomized as 0 – 10y or greater than or equal to 11y. The 
serum AFP in ng/ml was defined as the measurement closest to, but not later than, the 
first surgical intervention prior to the start of chemotherapy.17 In prior analyses, multiple 
methods of defining the optimal cutpoints for AFP were examined, but none were more 
informative than the traditional cutpoint of > vs. ≤ 10,000 ng/ml. Stage was defined used 
the COG criteria.12 Histology was defined either as pure yolk sac tumor, 
choriocarcinoma, embryonal carcinoma, or mixed malignant GCT (containing one of 
these components with teratoma, or at least two of these components without teratoma). 
Site was defined as testicular, ovarian, or extragonadal GCT. In sensitivity analyses, we 
included only the patients on COG trials that used standard dose cisplatin and excluded 
any patient who had also received either cyclophosphamide or high dose cisplatin. 
 
Results 
A comparison of the patient characteristics treated on PEb vs. JEB is presented in Table 
1.  Because these data represent the clinical trial data from two different clinical trial 
organziations and are not randomized trial, the patient characteristics are not balanced 
between the two regimens. Patients treated with carboplatin were more likely to be 
younger (61% were ages 0-4y vs. 49% in the cisplatin group), have extragonadal disease 
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(57% vs. 40%), pure yolk sac tumor (64% vs. 47%), pre-operative AFP >10,000 ng/ml 
(60% vs. 38 %) and stage IV disease (34% vs.24 %).  
 
In Table 2, the 4-year estimates of EFS and 95% confidence intervals (95% CI) are 
presented overall and by the univariate risk factors19. When the entire analytic population 
s considered, there is no significant difference in outcome between PEb (4y EFS 86%) vs. 
JEB (4y EFS 86%; HR 1.04; p=0.87). Risk of an event also was not significantly 
different in stratified univariate analyses defined by age, primary tumor site, histology, 
pre-operative AFP level, or stage.  
 
In Figure 1, we present EFS is presented as a forest plot of the hazard ratios in 
combinations of age, site and stage, as previously defined by MaGIC. (A table of EFS in 
these combined risk groups is included as Supplemental Table 2). The outcome 
comparing PEb vs. JEB did not exclude zero in any combination of age, stage or site. In 
some of the strata, the number of patients treated, particularly on the JEB regimen, was 
relatively small and consequently the confidence intervals are quite wide. Patients were 
also classified by the new MaGIC risk groups: SR1, SR2, and PR. The outcomes between 
JEB and PEb were again not significantly different in either SR1 [(HR) 1.50; p=0.20), 
SR2 (HR 1.34; p=0.55) or PR (HR 0.80; p=0.72)] (Supplemental Table 2). 
 
In Figure 2, the overall EFS survival curves are presented overall, for age, stage, site and 
by MaGIC risk group (SR1, SR2 and PR). EFS is not significantly different in any of 
these groups.  
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We performed multivariate modeling of outcome using the cure model17. After including 
in the model the variables for age, site and stage, the effect of treatment (PEb vs JEB) 
was not significant (estimated log odds -0.09; p=0.73) (Table 3). In sensitivity analysis, 
we included only patients treated with standard PEb (excluding patients treated with PEb 
+ cyclophosphamide on AGCT01P1 and patients treated with high dose cisplatin on 
INT0097) and none of the conclusions were significantly altered (data not shown). 
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Discussion 
No significant difference in outcome was observed among pediatric and adolescent 
extracranial GCT patients treated with a cisplatin-based regimen (PEb) vs. a carboplatin-
based regimen (JEB), when comparing groups by age, site and stage. Additionally, the 
treatment regimen received (cisplatin vs. carboplatin) was not significant in the results of 
the multivariate model (Table 3) that controls for the other known risk factors.  Although 
each individual risk stratum is relatively small in terms of patient numbers, in the absence 
of randomized data in this age group, we suggest that there is equipoise regarding the 
relative effectiveness of cisplatin vs. carboplatin for pediatric and adolescent GCT. 
 
Our conclusions differ from those observed in the four published randomized 
comparisons of cisplatin vs. carboplatin in adult men with non-seminomatous testicular 
germ cell tumors, which are summarized in Supplementary Table 3.7-10 There are several 
explanations for the observed differences. First of all, our results are not derived from a 
randomized trial but rather comprise an analysis of clinical trials conducted 
contemporaneously and thus are admittedly less conclusive. However, there are several 
aspects of the design of adult trials that predisposed the results to be unfavorable to 
carboplatin. Most importantly, all of the adult trials used a dose of carboplatin that was 
significantly lower than the dose used in the pediatric regimens (AUC 3-5 vs. AUC 7.9 or 
350-500 mg/m2  vs.600 mg/m2). The dose employed in the adult trials may therefore have 
been insufficient. Secondly, 2 7,10 of the 4 trials administered the carboplatin every 28 
days whereas the cisplatin regimen was administered every 21 days. Inadequate dose-
density of the carboplatin arms may have predisposed the carboplatin arm to do worse. A 
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third trial 8 used a lower dose of etoposide on the carboplatin arm of the trial than on the 
cisplatin arm of the trial (360mg/m2 vs 500mg/m2). This lower dose of etoposide has 
been shown to produce inferior results by Grimison et al. 20 Although these adjustments 
(increased cycle length and decreased etoposide dose) were made to compensate for the 
expected increased myelotoxicity of carboplatin, both would be expected to bias the 
results against 
 
Another explanation for the apparent enhanced performance of carboplatin in pediatric 
GCTs is that the underlying biology of pediatric disease is different from adult GCTs.  In 
younger children, the histology is likely to be predominately yolk sac tumor whereas in 
adolescents and adults, the histology is generally “mixed”.  GCTs in younger patients 
show variable loss of imprinting (LOI) whereas GCTs of adolescents and adults, have 
more complete LOI, implying that the origin of the tumor occurred at a later stage in 
embryologic development..21 Using comparative genomic hybridization, GCTs arising in 
younger patients consistently show a loss of 1p and 6q, whereas post-pubertal children 
exhibit the pathognomonic amplification of 12p seen in adults.22 Gene expression 
profiling segregates pediatric vs. adult GCTs.22 The biology of pediatric GCTs may 
render these tumors more inherently sensitive to chemotherapy.23  
 
The study has its limitations. Although the data presented here are not derived from a 
randomized comparison, the data have been harmonized to provide the maximal 
comparability possible outside of an RCT.  The precision is greater among younger 
patients (age 10y and less) due to the larger sample size (n=507). The sample size in 
15 
 
patients aged 11y or older is smaller, however the analysis of 276 adolescents age 11y 
and older (233 treated with cisplatin, and 43 treated with carboplatin), there is no 
evidence that carboplatin is inferior (p=0.96).  
 
Based on the data available, a randomized controlled trial of carboplatin vs. cisplatin, 
using the pediatric carboplatin dosing and schedule, was deemed warranted and is 
underway (COG AGCT1531). In order to have sufficient sample size, particularly among 
children age 10y or less in whom the incidence of GCT is lower, enrollment from 
international sites is necessary. AGCT1531 will enroll patients from the United States, 
Canada, Australia, New Zealand, United Kingdom, TATA Memorial Hospital in 
Mumbai, and the Japanese Children’s Cancer Group in order to meet accrual goals. This 
trial will clarify the relative effectiveness of carboplatin vs. cisplatin in standard risk 
patients age 0-25y and will carefully document any associated toxicities. The intention is 
to facilitate patient-centered conversations in the future that can enumerate the trade-offs 
in terms of efficacy vs. toxicity of cisplatin vs. carboplatin.  
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Figure 1: Forrest plot showing estimates of hazard ratio (HR) of patients treated with Jeb vs PEb, according to prognostic risk groups. 
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Figure 2. Kaplan-Meier estimates of EFS of patients treated with PEb vs. JEb. Overall (2a), by 
age (2b), by stage (2c), by site (2d), by MaGIC risk group (2e) 
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Table 1: Patient characteristics treated with Cisplatin-based regimens (PEb) vs. Carboplatin-based 
regimens (JEB) in MaGIC.  
 Assigned Treatment  
 PEb (n; %) JEB (n, %) Total (%) 
Total 620 (79.2%)  163 (20.8%) 783 
Age (years)    
0 – 10 387 (62.4%) 120 (73.6%) 507 (64.7%) 
11+ 233 (37.6%) 43 (26.4%) 276 (35.3%) 
Site    
Testes 147 (23.7%) 16 (9.8%) 163 (20.8%) 
Ovarian 224 (36.1%) 54 (33.1%) 278 (35.5%) 
Extragonadal 
    Sacrococcygeal 
    Mediastinal 
    Other EG 
  249 (40.2%) 
  124 (20.0%) 
    56 (9.0%) 
    69 (11.1%) 
    93 (57.1%) 
    45 (27.6%) 
    13 (8.0%) 
    35 (21.5%) 
342 (43.7%) 
169 (21.6%) 
  69 (8.8%) 
104 (13.3%) 
Histology    
Embryonal Carcinoma 5 (0.8%) 3 (1.8%) 8 (1.0%) 
Yolk Sac 292 (47.1%) 104 (63.8%) 396 (50.6%) 
Choriocarcinoma 9 (1.4%) 1 (0.6%) 10 (1.3%) 
Mixed GCT 280 (45.2%) 55 (33.8%) 335 (42.8%) 
Other/Missing 34 (5.5%) 0 34 (4.3%) 
AFP    
0 – 9,999 358 (57.7%) 61 (37.4%) 419 (53.5%) 
>= 10,000 233 (37.6%) 98 (60.1%) 331 (42.3%) 
Missing 29 (4.7%) 4 (2.5%) 33 (4.2%) 
Stage    
I 125 (20.1%) 28 (17.2%) 153 (19.5%) 
II 129 (20.8%) 35 (21.5%) 164 (21.0%) 
III 218 (35.2%) 44 (27.0%) 262 (33.5%) 
IV 148 (23.9%) 56 (34.3%) 204 (26.0%) 
Treatment Regimena    
HD-PEb* 156 (25.2%) 0 156 (19.9%) 
PEb 450 (72.6%) 0 450 (57.5%) 
C-PEb** 14 (2.2%) 0 14 (1.8%) 
JEb 0 163 (100%) 163 (20.8%) 
             *HD-PEb: PEb with high dose cisplatin (200 mg/m2) 
             ** C-PEb: PEb plus cyclophosphamide 
 
 
22 
 
Table 2: Comparison of 4-year KM EFS (95% Confidence Intervals) in Patients Treated with 
cisplatin (PEb) vs. carboplatin (JEB).  
 Assigned Treatment   
 
PEb (4-year KM 
EFS; 95% CI) 
JEb (4-year KM 
EFS; 95% CI) 
p-Value 
HR*       (95% CI) 
Overall 
0.86 (0.83-0.89) 
N=620 
0.86 (0.79-0.90) 
N=163 
0.87 
1.04     (0.65-1.65) 
Age (years)     
<11 
0.89 (0.86-0.92) 
N=387 
0.87 (0.80-0.92) 
N=120 
0.54 
1.20     (0.66-2.18) 
>= 11 years 
0.81 (0.75-0.86) 
N=233 
0.81 (0.66-0.90) 
N=43 
0.96 
0.98     (0.46-2.09) 
Site     
Testes 
0.85 (0.78-0.90) 
N=147 
1 
N=16 
0.10 
0.185** 
(0.001-1.332) 
Ovarian 
0.90 (0.85-0.93) 
N=224 
0.85 (0.73-0.92) 
N=54 
0.38 
1.43     (0.64-3.22) 
Extragonadal 
 
Sacrococcygeal 
 
Mediastinal 
 
Other EG 
 
0.84 (0.79-0.88) 
N=249 
0.88 (0.81-0.92) 
N=124 
0.77 (0.63-0.86) 
N=56 
0.83 (0.72-0.90) 
N=69 
0.84 (0.74-0.90) 
N=93 
0.86 (0.72-0.94) 
N=45 
0.77 (0.44-0.92) 
N=13 
0.83 (0.66-0.92) 
N=35 
0.85 
 
0.80 
 
0.93 
 
0.87 
 
1.06     (0.58-1.93) 
1.13     (0.44-2.91) 
1.06     (0.30-3.76) 
1.08     (0.40-2.93) 
Histology     
Yolk Sac 
0.88 (0.84-0.91) 
N=292 
0.87 (0.79-0.92) 
N=104 
0.85 
1.06     (0.56-2.01) 
Mixed GCT 
0.85 (0.81-0.89) 
N=280 
0.84 (0.71-0.91) 
N=55 
0.80 
1.10     (0.53-2.27) 
AFP     
0 – 9,999 
0.89 (0.85-0.92) 
N=358 
0.93 (0.83-0.97) 
N=61 
0.25 
0.55     (0.20-1.54) 
>= 10,000 
0.84 (0.78-0.88) 
N=233 
0.80 (0.71-0.87) 
N=98 
0.37 
1.29     (0.74-2.24) 
Stage     
I 
0.90 (0.83-0.94) 
N=125 
1 
N=28 
0.09 
0.17** (0.001-1.268) 
II 
0.92 (0.85-0.96) 
N=129 
0.94 (0.79-0.99)  
N=35 
0.66 
0.71     (0.16-3.26) 
III 
0.87 (0.81-0.91) 
N=218 
0.82 (0.67-0.90) 
N=44 
0.34 
1.46     (0.66-3.21) 
IV 
0.78 (0.71-0.84) 
N=148 
0.76 (0.63-0.86) 
N=56 
0.86 
1.06     (0.56-2.01) 
*PEb is the reference group 
** Estimated using the method of Firth 
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Table 3: “CURE” model of prognostic factors for pediatric germ cell tumors, including treatment 
with either cisplatin (PEb) or carboplatin (JEb) 
 
 
Factor Characteristic Estimated Log 
Odds  
(p value) 
Chemotherapy PEb - 
JEb -0.09 (0.73) 
Tumor Site Testicular - 
Ovarian 0.61 (0.25) 
Extra gonadal 0.15 (0.70) 
Tumor Site by 
Age Interaction 
Testicular and 
11+ Years 
- 
Ovarian and 11+ 
Years 
-0.90 (0.18) 
Extragonadal and 
11+ Years 
-1.48 (0.02) 
Extent of 
Disease 
  
Stage I-III - 
Stage IV -1.00 (0.001) 
Age at 
Enrollment 
10 years of age or 
less 
- 
11 years of age or 
older 
-0.16 (0.73) 
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Supplemental Table 1: Pediatric Germ Cell Tumor Clinical Trials included in MaGIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National 
Group 
 
Eligibility of the Trial 
Treatment 
Regimen 
Cycle 
(days) 
Number of 
cycles 
Number 
of 
patients 
GC124 
24 
UK All patients with 
MGCT 
Etoposide 
120mg/m2 D1-3, 
Bleomycin 15 
IU/m2 D2,  
Cisplatin 100mg/m2 
D1 
21  n* + 2 
(n=courses to 
marker 
normalization) 
21  
GC225 
UK All patients with 
MGCT 
JEB 21  n* + 2 163  
INT-106/ 
POG9048/CCG-
889114 
US Stage II testicular; 
Stage I-II ovarian 
PEB 21  4 (+2 if PR) 118  
INT-0097/ 
POG9049/CCG-
888226 
US Stage III and IV 
gonadal and 
extragonadal tumors 
PEB vs. HDPEB 21  4 (+2 if PR) 261  
P974927 
US Stage III and IV 
extragonadal tumors 
Amifostine 
825mg/m2 D1-5 + 
HDPEB 
21  4 (+2 if PR) 26 
AGCT01P128 
US Stage III and IV 
extragonadal tumors 
C-BEP 21  4 (+2 if PR) 14 
AGCT013229 US Stage I-III ovarian 
Stage I-IV testicular 
Stage I-II extragonadal 
Compressed PEB 21  3 (+3 if PR) 180  
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Supplemental Table 2: Comparison of 4-year KM EFS (95% Confidence Intervals) of Pediatric 
GCT Patients Treated with cisplatin (PEb) vs. carboplatin (JEB). 
  Assigned Treatment   
Tumor 
Site Stage and Age 
PEb (4-year 
KM EFS; 95% 
CI) 
JEb (4-year KM 
EFS; 95% CI) 
p-Value 
HR*        (95% 
CI) 
Ovarian Stage I-III, Age 
< 11 
0.95 (0.86-0.98)  
N=78 
1 
N=18 
0.32 
0.45 (0.003-
4.25)**  
Ovarian Stage IV, Age < 
11 
0.80 (0.20-0.97) 
N=5 
0.67 (0.05-0.95) 
N=3 
0.78 
1.49     (0.09-
23.94) 
Ovarian Stage I-III, Age 
>= 11 
0.87 (0.80-0.92) 
N=138 
0.81 (0.61-0.92) 
N=27 
0.41 
1.52     (0.56-
4.14) 
Ovarian Stage IV, Age 
>= 11 
1 
N=3 
0.67 (0.19-0.90) 
N=6 
0.90 
1.17     (0.11-
12.98) 
Testicular Stage I-III, Age 
< 11 
0.87 (0.77-0.93) 
N=78 
1 
N=5 
0.40 
0.68 (0.005-
5.31)**--- 
Testicular Stage IV, Age < 
11 
0.93 (0.59-0.99) 
N=14 
1 
N=4 
0.59 
1.22 (0.008-
21.88)**--- 
Testicular Stage I-III, Age 
>= 11 
0.91 (0.68-0.97) 
N=23 
1 
N=6 
0.45 
0.71 (0.005-
8.78)**--- 
Testicular Stage IV, Age 
>= 11 
0.72 (0.53-0.84) 
N=32 
1 
N=1 
0.57 
1.46 (0.01-
11.51)**--- 
EG Stage I-III, Age 
< 11 
0.92 (0.85-0.96) 
N=129 
0.92 (0.80-0.97) 
N=49 
0.95 
1.04     (0.32-
3.30) 
EG Stage IV, Age < 
11 
0.83 (0.73-0.90) 
N=83 
0.75 (0.59-0.86) 
N=41 
0.29 
1.55     (0.69-
3.48) 
EG Stage I-III, Age 
>= 11 
0.72 (0.49-0.86) 
N=26 
0.50 (0.01-0.91) 
N=2 
0.46 
2.17     (0.26-
17.75) 
EG Stage IV, Age 
>= 11 
0.30 (0.06-0.60) 
N=11 
1 
N=1 
0.45 
0.80 (0.006-
7.06)**--- 
Overall Stage I-III, Age 
< 11 
0.91 (0.87-0.94)  
N=285 
0.94 (0.86-0.98) 
N=72 
0.40 
0.64     (0.22-
1.83) 
Overall Stage IV, Age < 
11 
0.84 (0.76-0.90) 
N=102 
0.77 (0.62-0.86) 
N=48 
0.28 
1.52     (0.71-
3.28) 
Overall Stage I-III, Age 
>= 11 
0.85 (0.79-0.90) 
N=187 
0.83 (0.66-0.92) 
N=35 
0.68 
1.21     (0.50-
2.94) 
Overall Stage IV, Age 
>= 11 
0.65 (0.49-0.77) 
N=46 
0.75 (0.31-0.93) 
N=8 
0.61 
0.68     (0.16-
2.97) 
MaGIC 
Risk 
Group 
Standard Risk 1 
0.90 (0.85-0.93) 
N=303 
0.85 (0.76-0.91) 
N=100 
0.20 
1.50     (0.81-
2.77) 
Standard Risk 2 
0.85 (0.77-0.90) 
N=143 
0.80 (0.58-0.91) 
N=25 
0.55 
1.34     (0.50-
3.58) 
Poor Risk 
0.62 (0.46-0.74) 
N=49 
0.70 (0.33-0.89) 
N=10 
0.72 
0.80     (0.24-
2.71) 
*PEb is the reference group 
** Estimated using the method of Firth  
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Supplementary Table 3. Characteristics of RCT of Carboplatin vs. Cisplatin in Men with “Good Risk” NS-GCT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Differences among the two treatment arms other than the choice of platinum agent are shown in bold. 
 
 20% of the initial patients in this trial were treated with a dose of carboplatin <500 mg/m2  
 Time-interval was not reported. 
 Only the first 22 patients in the cis-platin arm were randomized. The last 17 patients were “assigned” cisplatin because carboplatin was no 
longer available. 
 
AUC, area under the curve; B, bleomycin; C, carboplatin; CR, complete response; d, days; E, etoposide; EORTC, European Organization for 
Research and Treatment of Cancer; I, ifosfamide; IGCCCG, International Germ Cell Cancer Collaborative Group; MSKCC, Memorial Sloan-
Kettering Cancer Center; MRC, Medical Research Council; N/A, not available; NS, non-seminoma; P, cisplatin; S, seminoma; V, vinblastine.  
Study 
[Reference] 
Risk 
Criteria 
Histology Testes 
Site (%) 
No. of 
Patients 
Chemotherapy Regimen** Event-free 
survival 
Bajorin et al. 
[7] 
MSKCC NS+S 96 131 EC 
 
134 EP 
 
C 500 mg/ma and E 500 mg/m2 q28d x 4 
 
P 100 mg/m2 and E 500 mg/m2 q21d x 4 
74% at 3y 
 
87% at 3y* 
Tjulandin et 
al. 10] 
Indiana NS +S 95 23 EC 
 
39 EPc 
 
C 350 mg/m2 and E 500 mg/m2 q28d x 4 
 
P 100 mg/m2 and E 500 mg/m2 q21d x 4 
61%b 
 
79% 
Bokemeyer 
et al. [8] 
Indiana NS 100 25 CEB 
 
29 PEB 
C to achieve AUC 5 mg/mL/min, E 360 mg/m2, 
and B 90 mg q21d x 4c 
P 100 mg/m2, E 500 mg/m2 and B 90 mg q21d 
x 3  
63% at 2y 
 
74% at 2y* 
 
Horwich et 
al. [9] 
MRC / 
EORTC 
NS 100 298 
CEB 
 
300 
PEB 
C to achieve AUC 5 mg/mL/min, E 360 mg/m2 
and B 30 mg q21d x 4 
P 100 mg/m2, E 360 mg/m2 and B 30 mg q21d 
x 4 
77% at 1y 
 
91% at 1y 
